Charles River Laboratories International (NYSE:CRL) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

Charles River Laboratories International (NYSE:CRL) had its price objective increased by analysts at JPMorgan Chase & Co. from $165.00 to $190.00 in a research note issued to investors on Monday,Benzinga reports. The firm currently has a “neutral” rating on the medical research company’s stock. JPMorgan Chase & Co.‘s price target points to a potential downside of 2.66% from the stock’s current price.

Other equities research analysts have also issued reports about the stock. Evercore ISI increased their price objective on shares of Charles River Laboratories International from $190.00 to $200.00 and gave the company an “outperform” rating in a report on Friday, October 3rd. Mizuho upped their target price on shares of Charles River Laboratories International from $155.00 to $174.00 and gave the stock a “neutral” rating in a research report on Friday, October 17th. Barclays raised their target price on shares of Charles River Laboratories International from $210.00 to $215.00 and gave the company an “overweight” rating in a research note on Monday. Robert W. Baird upgraded shares of Charles River Laboratories International from a “neutral” rating to an “outperform” rating and boosted their price target for the stock from $178.00 to $199.00 in a research note on Thursday, November 6th. Finally, Bank of America raised shares of Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $225.00 price objective for the company in a report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $194.07.

Charles River Laboratories International Price Performance

NYSE:CRL opened at $195.20 on Monday. The business’s 50-day simple moving average is $178.36 and its two-hundred day simple moving average is $164.51. Charles River Laboratories International has a 52 week low of $91.86 and a 52 week high of $200.58. The stock has a market cap of $9.61 billion, a PE ratio of -125.13, a P/E/G ratio of 7.00 and a beta of 1.63. The company has a quick ratio of 1.10, a current ratio of 1.37 and a debt-to-equity ratio of 0.64.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, November 5th. The medical research company reported $2.43 earnings per share for the quarter, topping analysts’ consensus estimates of $2.32 by $0.11. The firm had revenue of $1 billion during the quarter, compared to analyst estimates of $990.43 million. Charles River Laboratories International had a positive return on equity of 15.78% and a negative net margin of 2.07%.The business’s quarterly revenue was down .5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.59 earnings per share. As a group, analysts forecast that Charles River Laboratories International will post 9.36 EPS for the current fiscal year.

Hedge Funds Weigh In On Charles River Laboratories International

Large investors have recently modified their holdings of the stock. Brooklyn Investment Group raised its holdings in Charles River Laboratories International by 93.5% during the 1st quarter. Brooklyn Investment Group now owns 178 shares of the medical research company’s stock valued at $27,000 after buying an additional 86 shares during the period. Cromwell Holdings LLC increased its position in Charles River Laboratories International by 542.9% during the second quarter. Cromwell Holdings LLC now owns 180 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 152 shares during the last quarter. Neo Ivy Capital Management bought a new position in Charles River Laboratories International during the second quarter valued at $29,000. Rothschild Investment LLC raised its stake in shares of Charles River Laboratories International by 82.4% in the third quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 84 shares during the period. Finally, Atlantic Union Bankshares Corp bought a new stake in shares of Charles River Laboratories International in the 3rd quarter worth about $31,000. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).